Our Scientific Vision

Our goal is to digitize, decode, and decipher human biology to prevent, treat, or even cure chronic diseases and cancer.

Our Approach

Our Approach Image 1

At Viome, we use a systems biology approach to deeply understand the origin and progression of disease using gene expression (mRNA) analysis with a state-of-the-art AI platform.

Our Approach Image 2

Viome’s platform integrates mRNA molecular data and rich phenotype metadata from more than a quarter million samples to generate and test hypotheses related to many chronic diseases and cancers. This enables us to discover biomarkers and biological insights for a range of chronic diseases and cancers at an unprecedented rate.

Screen Shot 2021-09-13 at 12.24.54 PM

Our discoveries include early molecular signatures for over 30 diseases and biological states of interest, including oral and throat cancers, colorectal cancers, skin, breast cancers, chronic diseases such as Type 2 Diabetes, IBS, IBD, Depression/MDD, Anxiety, Obesity, Hashimoto’s disease, OsteoArthritis, Acne, and more.

Each of these early discoveries is a starting point for rigorous clinical studies at Viome. Once we discover biomarkers using our platform, we launch clinical studies and work with partners in our network to validate these hypotheses using clinical gold standards.

What is mRNA?

Messenger RNA, or mRNA, plays a fundamental role in human biology, transferring the instructions stored in DNA to make the proteins required in every living cell. Our approach is to use mRNA medicines to instruct a patient’s own cells to produce proteins that could prevent, treat, or cure disease.

VLS Our Science Lab Image

The Five Pillars of Viome Life Sciences


Our direct-to-consumer service analyzes gene expressions (mRNA) in order to provide individuals with health insights and precision nutrition to live a healthier life.

This platform of ~300,000 samples enables us to enhance our understanding of human biology as a system in order to develop predictive biomarkers, precision diagnostics, and precision therapeutics to prevent and intercept chronic diseases.


Based on the longitudinal data from our testing services, we are able to develop biomarkers for most chronic diseases, cancers, and aging. With every test we are able to see an individual’s progression towards or away from identified disease biomarkers.


Our predictive biomarkers provide us with the hypothesis to do clinical research and identify the signatures of chronic diseases, cancers, and aging.


This approach, based on the use of a companion diagnostic, would ensure the selection of patients with the highest chance of having a positive response to treatment. This approach could also help to identify incremental therapeutic measures aiming at the restoration of responsiveness to therapy.


The signatures found through diagnostics allow us to determine the mechanism of action to develop precision therapeutics in the form of drugs and vaccines.

Viome can determine drug effectiveness, including immunotherapy, which is dependent upon the gut microbiome.

Our Focus Areas

Viome's mRNA Platform

Increasing every day, Viome boasts access to an mRNA platform of more than a quarter million samples to generate and test hypotheses related to many chronic diseases and cancers. At our core, Viome focuses on establishing biological data trends that identify the patterns for optimal health. Our initiative integrates a robust dataset with innovative technology to determine causal relationships that evaluate and improve the current understanding of chronic diseases as we know them.

“For most common chronic diseases, we have thousands of people with those diseases, and thousands of people who are free from those diseases”.

- Guru Banavar, CTO

Our cohorts illuminate early discoveries of disease biomarkers that extract a molecular signal from the gut microbiome and blood transcriptome. With analytically validated biomarkers, new clinical study designs with specific populations of interest can generate innovative clinical validation against the gold standard and determine how we can improve the standard of care.

Learn what studies we have recently completed enabling us to potentiate the clinical relevance of our mRNA technology to meaningfully improve how diseases can be predicted, diagnosed, and treated.

VLS Our Science Sample Image LG

Viome's Sample and Data Process

Every sample is processed in Viome’s CLIA-licensed laboratory to extract mRNA molecules from both microbial and human cells, which are then sequenced to produce high resolution and high quality sample data. All sample types (stool, blood, saliva, plasma, spinal fluid, vaginal swabs, urine, tissue biopsies, etc) are processed using the same underlying sample to result process on Viome’s CLIA-approved mRNA platform. RNA molecules are preserved robustly for 4 weeks at ambient temperatures.

Viome’s AI & mRNA Platform: The Ultimate Data Analysis Tool on the Market

Viome offers a highly accurate, yet evolving analysis of the host/microbiome data for molecular biomarker discovery and clinical application development.

VLS Our Science RNA Platform Image

All sample data is processed through Viome’s bioinformatics pipeline to map sequencing reads to molecular features -- genes for human transcripts, gene clusters and genomes for microbial transcripts. Molecular features are then analyzed to determine biological pathways of interest. Molecular features and pathways are used to develop AI/ML models that discover molecular signatures using clinical meta-data for samples, and finally, the discovered biomarkers are clinically validated using clinical gold standards. Viome’s AI looks for, in an unbiased manner, the full range of biological functions in mRNA samples, and in particular, the interaction between microbiome and host functions.